Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Thomas Hensing

TitleCLINICAL ASSOCIATE PROFESSOR
InstitutionUniversity of Chicago
DepartmentMedicine
AddressChicago IL 60637
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Rosenberg AJ, Rademaker A, Hochster HS, Ryan T, Hensing T, Shankaran V, Baddi L, Mahalingam D, Mulcahy MF, Benson AB. Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up. Oncologist. 2019 Aug; 24(8):1039-e642. PMID: 31138725.
      View in: PubMed
    2. Guo NL, Dowlati A, Raese RA, Dong C, Chen G, Beer DG, Shaffer J, Singh S, Bokhary U, Liu L, Howington J, Hensing T, Qian Y. A Predictive 7-Gene Assay and Prognostic Protein Biomarkers for Non-small Cell Lung Cancer. EBioMedicine. 2018 Jun; 32:102-110. PMID: 29861409.
      View in: PubMed
    3. Shah S, Wood K, Labadie B, Won B, Brisson R, Karrison T, Hensing T, Kozloff M, Bao R, Patel JD, Luke JJ. Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer. Oncotarget. 2018 Jan 12; 9(4):4375-4384. PMID: 29435109.
      View in: PubMed
    4. Shah S, Wood K, Brisson R, Karrison T, Hensing T, Luke JJ, Patel JD. PS01.63: Clinical Characteristics of Acquired Resistance with Anti-PD-1/PD-L1 in Non-Small Cell Lung Cancer (NSCLC): Topic: Medical Oncology. J Thorac Oncol. 2016 Nov; 11(11S):S310. PMID: 27969530.
      View in: PubMed
    5. Wood K, Hensing T, Salgia R. KRAS in Non-Small-Cell Lung Cancer-Reply. JAMA Oncol. 2016 10 01; 2(10):1373-1374. PMID: 27442777.
      View in: PubMed
    6. Campbell NP, Hensing TA, Bhayani MK, Shaikh AY, Brockstein BE. Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck. Expert Rev Anticancer Ther. 2016 Aug; 16(8):847-58. PMID: 27400139.
      View in: PubMed
    7. Wood K, Hensing T, Malik R, Salgia R. Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review. JAMA Oncol. 2016 Jun 01; 2(6):805-12. PMID: 27100819.
      View in: PubMed
    8. Ali SM, Hensing T, Schrock AB, Allen J, Sanford E, Gowen K, Kulkarni A, He J, Suh JH, Lipson D, Elvin JA, Yelensky R, Chalmers Z, Chmielecki J, Peled N, Klempner SJ, Firozvi K, Frampton GM, Molina JR, Menon S, Brahmer JR, MacMahon H, Nowak J, Ou SH, Zauderer M, Ladanyi M, Zakowski M, Fischbach N, Ross JS, Stephens PJ, Miller VA, Wakelee H, Ganesan S, Salgia R. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. Oncologist. 2016 06; 21(6):762-70. PMID: 27245569.
      View in: PubMed
    9. Vigneswaran J, Tan YH, Murgu SD, Won BM, Patton KA, Villaflor VM, Hoffman PC, Hensing T, Hogarth DK, Malik R, MacMahon H, Mueller J, Simon CA, Vigneswaran WT, Wigfield CH, Ferguson MK, Husain AN, Vokes EE, Salgia R. Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation. Oncotarget. 2016 Apr 05; 7(14):18876-86. PMID: 26934441.
      View in: PubMed
    10. Won B, Carey GB, Tan YH, Bokhary U, Itkonen M, Szeto K, Wallace J, Campbell N, Hensing T, Salgia R. The Chicago Thoracic Oncology Database Consortium: A Multisite Database Initiative. Cureus. 2016 Mar 16; 8(3):e533. PMID: 27092293.
      View in: PubMed
    11. Dizon DS, Krilov L, Cohen E, Gangadhar T, Ganz PA, Hensing TA, Hunger S, Krishnamurthi SS, Lassman AB, Markham MJ, Mayer E, Neuss M, Pal SK, Richardson LC, Schilsky R, Schwartz GK, Spriggs DR, Villalona-Calero MA, Villani G, Masters G. Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2016 Mar 20; 34(9):987-1011. PMID: 26846975.
      View in: PubMed
    12. Rosenberg CA, Flanagan C, Brockstein B, Obel JC, Dragon LH, Merkel DE, Wade EL, Law TM, Khandekar JD, Hensing TA. Promotion of self-management for post treatment cancer survivors: evaluation of a risk-adapted visit. J Cancer Surviv. 2016 Feb; 10(1):206-19. PMID: 26178325.
      View in: PubMed
    13. Lennon FE, Cianci GC, Cipriani NA, Hensing TA, Zhang HJ, Chen CT, Murgu SD, Vokes EE, Vannier MW, Salgia R. Lung cancer-a fractal viewpoint. Nat Rev Clin Oncol. 2015 Nov; 12(11):664-75. PMID: 26169924.
      View in: PubMed
    14. Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol. 2015 Jan; 10(1 Suppl 1):S1-63. PMID: 25535693.
      View in: PubMed
    15. Obel J, Brockstein B, Marschke M, Robicsek A, Konchak C, Sefa M, Ziomek N, Benfield T, Peterson C, Gustafson C, Eriksson J, Harper A, Tabachow C, Raymond M, Hensing T. Outpatient advance care planning for patients with metastatic cancer: a pilot quality improvement initiative. J Palliat Med. 2014 Nov; 17(11):1231-7. PMID: 25343403.
      View in: PubMed
    16. Radosevich AJ, Mutyal NN, Rogers JD, Gould B, Hensing TA, Ray D, Backman V, Roy HK. Buccal spectral markers for lung cancer risk stratification. PLoS One. 2014; 9(10):e110157. PMID: 25299667.
      View in: PubMed
    17. Somaiah N, Fidler MJ, Garrett-Mayer E, Wahlquist A, Shirai K, Buckingham L, Hensing T, Bonomi P, Simon GR. Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung. Oncoscience. 2014; 1(8):522-528. PMID: 25594059.
      View in: PubMed
    18. Wali RK, Hensing TA, Ray DW, Dela Cruz M, Tiwari AK, Radosevich A, Jepeal L, Fernando HC, Litle VR, Charlot M, Momi N, Backman V, Roy HK. Buccal microRNA dysregulation in lung field carcinogenesis: gender-specific implications. Int J Oncol. 2014 Sep; 45(3):1209-15. PMID: 24919547.
      View in: PubMed
    19. Shtivelman E, Hensing T, Simon GR, Dennis PA, Otterson GA, Bueno R, Salgia R. Molecular pathways and therapeutic targets in lung cancer. Oncotarget. 2014 Mar 30; 5(6):1392-433. PMID: 24722523.
      View in: PubMed
    20. Hensing T, Chawla A, Batra R, Salgia R. A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization. Adv Exp Med Biol. 2014; 799:85-117. PMID: 24292963.
      View in: PubMed
    21. Goss GD, O'Callaghan C, Lorimer I, Tsao MS, Masters GA, Jett J, Edelman MJ, Lilenbaum R, Choy H, Khuri F, Pisters K, Gandara D, Kernstine K, Butts C, Noble J, Hensing TA, Rowland K, Schiller J, Ding K, Shepherd FA. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J Clin Oncol. 2013 Sep 20; 31(27):3320-6. PMID: 23980091.
      View in: PubMed
    22. Hensing TA, Salgia R. Molecular biomarkers for future screening of lung cancer. J Surg Oncol. 2013 Oct; 108(5):327-33. PMID: 23893423.
      View in: PubMed
    23. Socinski MA, Evans T, Gettinger S, Hensing TA, VanDam Sequist L, Ireland B, Stinchcombe TE. Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May; 143(5 Suppl):e341S-e368S. PMID: 23649446.
      View in: PubMed
    24. Carey GB, Kazantsev S, Surati M, Rolle CE, Kanteti A, Sadiq A, Bahroos N, Raumann B, Madduri R, Dave P, Starkey A, Hensing T, Husain AN, Vokes EE, Vigneswaran W, Armato SG, Kindler HL, Salgia R. Utilisation of a thoracic oncology database to capture radiological and pathological images for evaluation of response to chemotherapy in patients with malignant pleural mesothelioma. BMJ Open. 2012; 2(5). PMID: 23103606.
      View in: PubMed
    25. Stinchcombe TE, Peterman AH, Lee CB, Moore DT, Beaumont JL, Bradford DS, Bakri K, Taylor M, Crane JM, Schwartz G, Hensing TA, McElroy E, Niell HB, Harper HD, Pal S, Socinski MA. A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age =70 years) with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol. 2011 Sep; 6(9):1569-77. PMID: 21716146.
      View in: PubMed
    26. Tan EH, Goss GD, Salgia R, Besse B, Gandara DR, Hanna NH, Yang JC, Thertulien R, Wertheim M, Mazieres J, Hensing T, Lee C, Gupta N, Pradhan R, Qian J, Qin Q, Scappaticci FA, Ricker JL, Carlson DM, Soo RA. Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011 Aug; 6(8):1418-25. PMID: 21597387.
      View in: PubMed
    27. Brockstein B, Hensing T, Carro GW, Obel J, Khandekar J, Kaminer L, Van De Wege C, de Wilton Marsh R. Effect of an electronic health record on the culture of an outpatient medical oncology practice in a four-hospital integrated health care system: 5-year experience. J Oncol Pract. 2011 Jul; 7(4):e20-4. PMID: 22043197.
      View in: PubMed
    28. Yount S, Beaumont J, Rosenbloom S, Cella D, Patel J, Hensing T, Jacobsen PB, Syrjala K, Abernethy AP. A brief symptom index for advanced lung cancer. Clin Lung Cancer. 2012 Jan; 13(1):14-23. PMID: 21729652.
      View in: PubMed
    29. Salgia R, Hensing T, Campbell N, Salama AK, Maitland M, Hoffman P, Villaflor V, Vokes EE. Personalized treatment of lung cancer. Semin Oncol. 2011 Apr; 38(2):274-83. PMID: 21421117.
      View in: PubMed
    30. Surati M, Robinson M, Nandi S, Faoro L, Demchuk C, Rolle CE, Kanteti R, Ferguson BD, Hasina R, Gangadhar TC, Salama AK, Arif Q, Kirchner C, Mendonca E, Campbell N, Limvorasak S, Villaflor V, Hensing TA, Krausz T, Vokes EE, Husain AN, Ferguson MK, Karrison TG, Salgia R. Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database. J Clin Bioinforma. 2011 Feb 28; 1(8):1-11. PMID: 21603121.
      View in: PubMed
    31. Mollberg N, Surati M, Demchuk C, Fathi R, Salama AK, Husain AN, Hensing T, Salgia R. Mind-mapping for lung cancer: towards a personalized therapeutics approach. Adv Ther. 2011 Mar; 28(3):173-94. PMID: 21337123.
      View in: PubMed
    32. Surati M, Robinson M, Nandi S, Faoro L, Demchuk C, Kanteti R, Ferguson B, Gangadhar T, Hensing T, Hasina R, Husain A, Ferguson M, Karrison T, Salgia R. Generation of comprehensive thoracic oncology database--tool for translational research. J Vis Exp. 2011 Jan 22; (47). PMID: 21304468.
      View in: PubMed
    33. Roy HK, Hensing T, Backman V. Nanocytology for field carcinogenesis detection: novel paradigm for lung cancer risk stratification. Future Oncol. 2011 Jan; 7(1):1-3. PMID: 21174531.
      View in: PubMed
    34. Roy HK, Subramanian H, Damania D, Hensing TA, Rom WN, Pass HI, Ray D, Rogers JD, Bogojevic A, Shah M, Kuzniar T, Pradhan P, Backman V. Optical detection of buccal epithelial nanoarchitectural alterations in patients harboring lung cancer: implications for screening. Cancer Res. 2010 Oct 15; 70(20):7748-54. PMID: 20924114.
      View in: PubMed
    35. Stinchcombe TE, Bradford DS, Hensing TA, LaRocca RV, Saleh M, Evans T, Bakri K, Socinski MA. A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer. Cancer Invest. 2010 Feb; 28(2):208-15. PMID: 19916742.
      View in: PubMed
    36. Eilers RE, Gandhi M, Patel JD, Mulcahy MF, Agulnik M, Hensing T, Lacouture ME. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst. 2010 Jan 06; 102(1):47-53. PMID: 20007525.
      View in: PubMed
    37. Subramanian H, Roy HK, Pradhan P, Goldberg MJ, Muldoon J, Brand RE, Sturgis C, Hensing T, Ray D, Bogojevic A, Mohammed J, Chang JS, Backman V. Nanoscale cellular changes in field carcinogenesis detected by partial wave spectroscopy. Cancer Res. 2009 Jul 01; 69(13):5357-63. PMID: 19549915.
      View in: PubMed
    38. Patel JD, Hensing TA, Rademaker A, Hart EM, Blum MG, Milton DT, Bonomi PD. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol. 2009 Jul 10; 27(20):3284-9. PMID: 19433684.
      View in: PubMed
    39. Hensing TA, Subramanian H, Roy HK, Breault D, Bogojevic Z, Ray D, Hasabou N, Backman V. Identification of malignancy-associated change in buccal mucosa with partial wave spectroscopy (PWS): A potential biomarker for lung cancer risk. J Clin Oncol. 2008 May 20; 26(15_suppl):11045. PMID: 27947658.
      View in: PubMed
    40. Patel JD, Hensing TA, Rademaker F, Hart E, Obasaju CK, Treat J, Milton D, Bonomi PD. Pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC). J Clin Oncol. 2008 May 20; 26(15_suppl):8044. PMID: 27949033.
      View in: PubMed
    41. Stinchcombe TE, Harper HD, Hensing TA, Moore DT, Crane JM, Atkins JN, Willard EM, Detterbeck FC, Socinski MA. The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected non-small cell lung cancer. J Thorac Oncol. 2008 Feb; 3(2):145-51. PMID: 18303435.
      View in: PubMed
    42. Lilenbaum RC, Cashy J, Hensing TA, Young S, Cella D. Prevalence of poor performance status in lung cancer patients: implications for research. J Thorac Oncol. 2008 Feb; 3(2):125-9. PMID: 18303431.
      View in: PubMed
    43. Cella D, Eton D, Hensing TA, Masters GA, Parasuraman B. Relationship between symptom change, objective tumor measurements, and performance status during chemotherapy for advanced lung cancer. Clin Lung Cancer. 2008 Jan; 9(1):51-8. PMID: 18282359.
      View in: PubMed
    44. Baggstrom MQ, Stinchcombe TE, Fried DB, Poole C, Hensing TA, Socinski MA. Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol. 2007 Sep; 2(9):845-53. PMID: 17805063.
      View in: PubMed
    45. Davis K, Yount S, Del Ciello K, Whalen M, Khan S, Bass M, Du H, Eton D, Masters G, Hensing T, Cella D. An innovative symptom monitoring tool for people with advanced lung cancer: a pilot demonstration. J Support Oncol. 2007 Sep; 5(8):381-7. PMID: 17944147.
      View in: PubMed
    46. Cella D, Wagner L, Cashy J, Hensing TA, Yount S, Lilenbaum RC. Should health-related quality of life be measured in cancer symptom management clinical trials? Lessons learned using the functional assessment of cancer therapy. J Natl Cancer Inst Monogr. 2007; (37):53-60. PMID: 17951232.
      View in: PubMed
    47. Hensing TA, Hanna NH, Gillenwater HH, Gabriella Camboni M, Allievi C, Socinski MA. Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer. Anticancer Drugs. 2006 Jul; 17(6):697-704. PMID: 16917215.
      View in: PubMed
    48. Govindan R, Natale R, Wade J, Herbst R, Krebs A, Reiling R, Hensing T, Wozniak A, Belani CP, Kelly K, Ochs J. Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program. Lung Cancer. 2006 Sep; 53(3):331-7. PMID: 16797779.
      View in: PubMed
    49. Hoang T, Kim K, Merchant J, Traynor AM, McGovern J, Oettel KR, Sanchez FA, Ahuja HG, Hensing TA, Larson M, Schiller JH. Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2006 Mar; 1(3):218-25. PMID: 17409860.
      View in: PubMed
    50. Argiris A, Hensing T, Yeldandi A, Patel S, Raji A, Sturgis C, Masters G, Gooding W, Pins M, Kolesar J. Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story. J Thorac Oncol. 2006 Jan; 1(1):52-60. PMID: 17409827.
      View in: PubMed
    51. Socinski MA, Ivanova A, Bakri K, Wall J, Baggstrom MQ, Hensing TA, Mears A, Tynan M, Beaumont J, Peterman AH, Niell HB. A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. Ann Oncol. 2006 Jan; 17(1):104-9. PMID: 16249215.
      View in: PubMed
    52. Reiling RB, Natale R, Wade J, Herbst R, Hensing T, Belani CP, Kelly K, Ochs J, Govindan R, Wozniak A, Krebs A. Efficacy and safety of gefitinib in chemo-naive patients with non-small cell lung cancer (NSCLC) in an expanded access program (EAP). J Clin Oncol. 2005 Jun; 23(16_suppl):7094. PMID: 27944554.
      View in: PubMed
    53. Collichio F, Ollila D, Huck K, Mullen N, Shearer H, Turner E, Kelly H, Zeger E, Socinski M, Hensing T. A phase II trial of weekly 1-hour paclitaxel in stage IV melanoma. J Clin Oncol. 2005 Jun; 23(16_suppl):7565. PMID: 27946033.
      View in: PubMed
    54. Hensing TA. Clinical evaluation and staging of patients who have lung cancer. Hematol Oncol Clin North Am. 2005 Apr; 19(2):219-35, v. PMID: 15833404.
      View in: PubMed
    55. Gillenwater HH, Stinchcombe TE, Qaqish BF, Tyann M, Hensing TA, Socinski MA. A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer. Lung Cancer. 2005 Mar; 47(3):413-9. PMID: 15713525.
      View in: PubMed
    56. Hensing TA, Schell MJ, Lee JH, Socinski MA. Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer. Lung Cancer. 2005 Feb; 47(2):253-9. PMID: 15639724.
      View in: PubMed
    57. Fried DB, Morris DE, Poole C, Rosenman JG, Halle JS, Detterbeck FC, Hensing TA, Socinski MA. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol. 2004 Dec 01; 22(23):4837-45. PMID: 15570087.
      View in: PubMed
    58. Socinski MA, Morris DE, Halle JS, Moore DT, Hensing TA, Limentani SA, Fraser R, Tynan M, Mears A, Rivera MP, Detterbeck FC, Rosenman JG. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial. J Clin Oncol. 2004 Nov 01; 22(21):4341-50. PMID: 15514375.
      View in: PubMed
    59. Stitzenberg KB, Groben PA, Stern SL, Thomas NE, Hensing TA, Sansbury LB, Ollila DW. Indications for lymphatic mapping and sentinel lymphadenectomy in patients with thin melanoma (Breslow thickness < or =1.0 mm). Ann Surg Oncol. 2004 Oct; 11(10):900-6. PMID: 15383424.
      View in: PubMed
    60. Hensing TA, Peterman AH, Schell MJ, Lee JH, Socinski MA. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer. 2003 Aug 15; 98(4):779-88. PMID: 12910523.
      View in: PubMed
    61. Socinski MA, Baggstrom MQ, Hensing TA. Duration of therapy in advanced, metastatic non-small-cell lung cancer. Clin Adv Hematol Oncol. 2003 Jan; 1(1):33-8. PMID: 16227958.
      View in: PubMed
    62. Kwock L, Smith JK, Castillo M, Ewend MG, Cush S, Hensing T, Varia M, Morris D, Bouldin TW. Clinical applications of proton MR spectroscopy in oncology. Technol Cancer Res Treat. 2002 Feb; 1(1):17-28. PMID: 12614173.
      View in: PubMed
    63. Ewend MG, Carey LA, Morris DE, Harvey RD, Hensing TA. Brain metastases. Curr Treat Options Oncol. 2001 Dec; 2(6):537-47. PMID: 12057099.
      View in: PubMed
    64. Hensing TA, Detterbeck F, Socinski MA. The role of induction therapy in the management of resectable non-small cell lung cancer. Cancer Control. 2000 Jan-Feb; 7(1):45-55. PMID: 10740660.
      View in: PubMed
    65. Hensing TA, Socinski MA. Combined-modality therapy in the nonsurgical management of unresectable stage III non-small cell lung cancer. Curr Opin Pulm Med. 1999 Jul; 5(4):194-200. PMID: 10407686.
      View in: PubMed
    Hensing's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _